Assessment of efficacy, safety, and tolerability of 4-n-butylresorcinol 0.3% cream: an Indian multicentric study on melasma

Study Design

Subject Type

Human

Trial Design

Open-Label

Trial Duration

56 days

Participants

52 (52 completed)

Efficacy

Intervention(s)			Outcome		Method		Effect	Description
Rucinol			Melasma		Clinical grading		⇩	Sign in to read for free
Sign in to read for free

Study Summary